Vaccines are biologically prepared products, which provide active acquired immunity to diseases such as cholera, polio, rotavirus, smallpox, yellow fever and others. A vaccine comprise an agent resembling to the disease causing microorganism. The vaccines are generally developed from live attenuated or killed forms of the disease causing microorganism, its toxins, or its surface proteins.
Oral administration of vaccines is the most convenient way of vaccination, owing to the factors such as oral vaccines are non-invasive, safe, and suitable for all age groups, especially children. Oral vaccines are mostly preferred for mass vaccination and are mostly liquid filled in sachet or blister. Oral vaccines are commonly available for diseases such as typhoid, cholera, adenovirus, rotavirus, and others.
Global Oral Vaccines Market Drivers
Rising incidences of infections such as cholera, tuberculosis, and others are expected to propel growth of the oral vaccine market over the forecast period. For instance, according to the World Health Organization (WHO), 2019, around 1.3 million to 4.0 million cases of cholera and approximately 10 million cases of tuberculosis were reported globally in the year 2018.
Moreover, increasing government support towards new product approvals are expected to drive the oral vaccines market growth. For instance, in October 2018, Sanofi Pasteur received the prequalification status from the World Health Organization (WHO) for its inactivated Polio Vaccine (IPV), ShanIPV. The prequalification program ensures that the vaccines are safe and effective for the immunization programs. The prequalification status qualifies the vaccine ShanIPV for purchase by the agencies of the United Nations for various immunization programs.
Global Oral Vaccines Market Regional Insights
North America accounted for the largest market share in 2018, owing to development of new technologies for enhancing vaccine utility in the region. For instance, in February 2019, according to the journal of the American Chemical Society (ACS), Nano Letters, researchers have developed the oral vaccines coupled with micromotors. The micromotors prevent the active agents in the vaccines from acidic condition in stomach, in order to enhance the utility of the vaccines.
Asia Pacific is also expected to witness significant growth in oral vaccines market due to increasing government initiatives and various immunization campaigns. For instance, in August 2019, the United Nations International Children's Emergency Fund (UNICEF), reported that around 400,000 people including 65,000 children were vaccinated in a six day oral cholera vaccination campaign run by the local health authorities of Yemen in three cities of Yemen (Aden, Al Dhale’e, and Taizz).
Global Oral Vaccines Market – Competitive Landscape
Key player in oral vaccines market are focused on strategic mergers and acquisitions to promote their product in global market. For instance, in February 2019, Bharat Biotech acquired Chiron Behring vaccines, a manufacturer of rabies vaccine and subsidiary of GlaxoSmithKline. The acquisition enhanced Bharat Biotech offerings for rabies vaccine and strengthened its market presence.
Key players operating in the global oral vaccines market include GlaxoSmithKline, Sanofi, Merck, Serum Institute of India pvt ltd, Swiss serum and vaccine institute Brene, Janssen pharmaceuticals, Paxvax corporation ltd, Valneva Canada, Shanghai Bravo bio Co ltd, Abbott Biologicals, MSD, Novavax, and Takeda.
Global Oral Vaccine Market – Market Taxonomy
On the basis of vaccine type, the global oral vaccine market is segmented into:
On the basis of application, the global oral vaccines market is segmented into:
On the basis of end user, the global oral vaccines market is segmented into:
On the basis of region, the global oral vaccines market is segmented into: